Influenza A(H7N9) Virus Antibody Responses in Survivors 1 Year after Infection, China, 2017

Technical Appendix

Technical Appendix Table 1. Laboratory data for patients infected with influenza A(H7N9) virus on hospital admission, China, 2017*

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Flu A</th>
<th>H7</th>
<th>N9</th>
<th>Virus isolation</th>
<th>HA lineage</th>
<th>ALT, U/L</th>
<th>AST, U/L</th>
<th>Creat, μmol/L</th>
<th>Leukocyte, ( \times 10^9 )/L</th>
<th>CRP, mg/L</th>
<th>Temp, °C</th>
<th>Serum collection, d§</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>32.54</td>
<td>29.04</td>
<td>30.35</td>
<td>Yes</td>
<td>YRD†</td>
<td>23</td>
<td>31</td>
<td>60.9</td>
<td>4.41</td>
<td>29.8</td>
<td>39</td>
<td>6, 161, 258, 369</td>
</tr>
<tr>
<td>2</td>
<td>27.56</td>
<td>32.64</td>
<td>30.89</td>
<td>No</td>
<td>NA</td>
<td>63</td>
<td>41</td>
<td>50.6</td>
<td>9.7</td>
<td>13</td>
<td>38</td>
<td>10, 126, 242, 349</td>
</tr>
<tr>
<td>3</td>
<td>29.37</td>
<td>28.03</td>
<td>29.32</td>
<td>No</td>
<td>NA</td>
<td>31</td>
<td>34</td>
<td>34.8</td>
<td>5.2</td>
<td>35.7</td>
<td>39.5</td>
<td>8, 126, 230, 332</td>
</tr>
<tr>
<td>4</td>
<td>30.58</td>
<td>32.96</td>
<td>30.79</td>
<td>No</td>
<td>NA</td>
<td>63</td>
<td>54</td>
<td>72.2</td>
<td>4.1</td>
<td>22.5</td>
<td>39.3</td>
<td>7, 99, 204, 307</td>
</tr>
<tr>
<td>5</td>
<td>30.04</td>
<td>29.97</td>
<td>30.72</td>
<td>Yes</td>
<td>YRD†</td>
<td>34.3</td>
<td>141.9</td>
<td>49</td>
<td>2.7</td>
<td>15.3</td>
<td>39</td>
<td>5, 99, 203, 300</td>
</tr>
<tr>
<td>7</td>
<td>28.62</td>
<td>28.25</td>
<td>28.54</td>
<td>No</td>
<td>NA</td>
<td>19</td>
<td>28</td>
<td>38.1</td>
<td>4.2</td>
<td>22.7</td>
<td>38.5</td>
<td>8, 96</td>
</tr>
<tr>
<td>8</td>
<td>30.12</td>
<td>29.57</td>
<td>29.51</td>
<td>Yes</td>
<td>YRD†</td>
<td>113</td>
<td>118</td>
<td>70.8</td>
<td>4.12</td>
<td>197</td>
<td>40.5</td>
<td>7, 99, 203, 305</td>
</tr>
<tr>
<td>9</td>
<td>28.45</td>
<td>28.71</td>
<td>28.56</td>
<td>Yes</td>
<td>YRD†</td>
<td>21</td>
<td>61</td>
<td>55</td>
<td>2.53</td>
<td>63.5</td>
<td>42</td>
<td>7, 96, 195, 298</td>
</tr>
<tr>
<td>10</td>
<td>30.56</td>
<td>31.63</td>
<td>31.95</td>
<td>No</td>
<td>NA</td>
<td>36</td>
<td>24</td>
<td>92</td>
<td>4.67</td>
<td>54.6</td>
<td>39.9</td>
<td>14, 89, 193, 301</td>
</tr>
<tr>
<td>11</td>
<td>28.52</td>
<td>29.13</td>
<td>29.65</td>
<td>Yes</td>
<td>YRD†</td>
<td>15</td>
<td>16</td>
<td>50.6</td>
<td>3.59</td>
<td>31</td>
<td>39.9</td>
<td>7, 94, 194, 299</td>
</tr>
<tr>
<td>12</td>
<td>27.43</td>
<td>28.57</td>
<td>27.78</td>
<td>Yes</td>
<td>YRD†</td>
<td>119.7</td>
<td>142.1</td>
<td>86</td>
<td>7.76</td>
<td>113.92</td>
<td>39.5</td>
<td>7, 84</td>
</tr>
<tr>
<td>13</td>
<td>30.5</td>
<td>30.28</td>
<td>32.1</td>
<td>Yes</td>
<td>YRD†</td>
<td>219</td>
<td>53</td>
<td>64.5</td>
<td>4.1</td>
<td>67</td>
<td>39</td>
<td>8, 101, 189, 300</td>
</tr>
<tr>
<td>14</td>
<td>27.19</td>
<td>28.04</td>
<td>27.67</td>
<td>Yes</td>
<td>YRD†</td>
<td>21</td>
<td>54</td>
<td>108.6</td>
<td>4.55</td>
<td>70</td>
<td>40.5</td>
<td>6, 85, 189, 298</td>
</tr>
<tr>
<td>15</td>
<td>28.55</td>
<td>29.01</td>
<td>28.69</td>
<td>Yes</td>
<td>YRD†</td>
<td>45.7</td>
<td>56</td>
<td>33</td>
<td>4.92</td>
<td>15.42</td>
<td>40</td>
<td>19, 109, 214, 310</td>
</tr>
<tr>
<td>16</td>
<td>30.67</td>
<td>28.85</td>
<td>30.88</td>
<td>No</td>
<td>NA</td>
<td>33.5</td>
<td>80.5</td>
<td>57</td>
<td>4.92</td>
<td>14.68</td>
<td>39.5</td>
<td>17, 111, 215, 314</td>
</tr>
<tr>
<td>Patient no.</td>
<td>Flu A</td>
<td>H7</td>
<td>N9</td>
<td>Virus isolation</td>
<td>HA lineage</td>
<td>ALT, U/L</td>
<td>AST, U/L</td>
<td>Creat, μmol/L</td>
<td>Leukocyte, $\times 10^9$/L</td>
<td>CRP, mg/L</td>
<td>Temp, °C</td>
<td>Serum collection, d§</td>
</tr>
<tr>
<td>------------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>-----------------</td>
<td>------------</td>
<td>----------</td>
<td>----------</td>
<td>---------------</td>
<td>--------------------------</td>
<td>------------</td>
<td>----------</td>
<td>---------------------</td>
</tr>
<tr>
<td>17</td>
<td>28</td>
<td>28.45</td>
<td>29.51</td>
<td>Yes</td>
<td>YRD‡</td>
<td>39</td>
<td>54</td>
<td>61.5</td>
<td>15.7</td>
<td>86.3</td>
<td>39</td>
<td>10, 106, 210, 307</td>
</tr>
<tr>
<td>18</td>
<td>28.18</td>
<td>28.36</td>
<td>29.05</td>
<td>No</td>
<td>NA</td>
<td>54</td>
<td>40</td>
<td>63.1</td>
<td>4.3</td>
<td>13</td>
<td>39.6</td>
<td>10, 119, 209, 318</td>
</tr>
<tr>
<td>19</td>
<td>30.22</td>
<td>29.75</td>
<td>30.52</td>
<td>No</td>
<td>NA</td>
<td>46.3</td>
<td>78.5</td>
<td>52</td>
<td>2.75</td>
<td>13.33</td>
<td>39</td>
<td>8, 82, 186, 292</td>
</tr>
<tr>
<td>20</td>
<td>29.35</td>
<td>29.24</td>
<td>29.02</td>
<td>No</td>
<td>NA</td>
<td>210</td>
<td>157</td>
<td>84</td>
<td>2.3</td>
<td>115</td>
<td>40</td>
<td>11, 79, 192</td>
</tr>
<tr>
<td>21</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>39</td>
<td>82, 186, 285</td>
</tr>
<tr>
<td>22</td>
<td>27.15</td>
<td>27.03</td>
<td>27.13</td>
<td>No</td>
<td>NA</td>
<td>32.3</td>
<td>89.3</td>
<td>92</td>
<td>2.49</td>
<td>15.92</td>
<td>39.6</td>
<td>35, 149, 261</td>
</tr>
<tr>
<td>23</td>
<td>27.67</td>
<td>28.87</td>
<td>28.73</td>
<td>No</td>
<td>NA</td>
<td>55</td>
<td>51</td>
<td>52</td>
<td>5.9</td>
<td>22.4</td>
<td>39.8</td>
<td>9, 51, 147, 254</td>
</tr>
<tr>
<td>24</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>No</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>3.2</td>
<td>NA</td>
<td>40</td>
<td>6, 114, 211, 321</td>
</tr>
<tr>
<td>25</td>
<td>29.03</td>
<td>28.45</td>
<td>29.64</td>
<td>Yes</td>
<td>YRD‡</td>
<td>34</td>
<td>67</td>
<td>60.8</td>
<td>3.36</td>
<td>92.9</td>
<td>39</td>
<td>98, 195, 305</td>
</tr>
</tbody>
</table>

*ALT, alanine transaminase; AST, aspartate transaminase; Creat, creatinine; CRP, C-reactive protein; Ct, cycle threshold; leukocyte, leukocyte (leukocyte) count; NA, not available; temp, body temperature; YRD, Yangtze River Delta lineage.

†Ct values are based on virus levels detected in throat swabs of the patients.

‡Low pathogenicity avian influenza virus.

§After illness onset.
## Technical Appendix Figure Table 2. Radiographic findings for patients infected with influenza A(H7N9) virus, China, 2017*

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Radiographic findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Inflammation in both lungs</td>
</tr>
<tr>
<td>2</td>
<td>Inflammation in both lungs</td>
</tr>
<tr>
<td>3</td>
<td>Exudative lesions in both lungs, inflammation in left lung</td>
</tr>
<tr>
<td>4</td>
<td>Infection in both lungs</td>
</tr>
<tr>
<td>5</td>
<td>Infection in left lung, left pleural effusion</td>
</tr>
<tr>
<td>6</td>
<td>Infection in both lungs, pleural thickening in both sides, left pleural effusion</td>
</tr>
<tr>
<td>7</td>
<td>Inflammation in both lungs</td>
</tr>
<tr>
<td>8</td>
<td>Infection, consolidation, and effusion in both lungs</td>
</tr>
<tr>
<td>9</td>
<td>Inflammation in both lungs</td>
</tr>
<tr>
<td>10</td>
<td>Inflammation in both lungs</td>
</tr>
<tr>
<td>11</td>
<td>Multi-patchy high-density shadow in both lungs</td>
</tr>
<tr>
<td>12</td>
<td>Inflammation in both lungs</td>
</tr>
<tr>
<td>13</td>
<td>Infection and consolidation in left lung</td>
</tr>
<tr>
<td>14</td>
<td>Infection and interstitial inflammation in right lower lung</td>
</tr>
<tr>
<td>15</td>
<td>Large high-density shadow and consolidation in two lungs</td>
</tr>
<tr>
<td>16</td>
<td>Infection in two lungs</td>
</tr>
<tr>
<td>17</td>
<td>Pneumonia in two lungs and particularly the right lung</td>
</tr>
<tr>
<td>18</td>
<td>Pneumonia in right lower lung</td>
</tr>
<tr>
<td>19</td>
<td>Ground-glass opacity in 2 lungs</td>
</tr>
<tr>
<td>20</td>
<td>Infection, emphysema, bullae in 2 lungs. Hydropneumothorax in right lung, effusion in left lung</td>
</tr>
<tr>
<td>21</td>
<td>NA</td>
</tr>
<tr>
<td>22</td>
<td>Consolidation in right lower lung. Hydropneumothorax with pulmonary atelectasis in right lung</td>
</tr>
<tr>
<td>23</td>
<td>Pneumonia in right lower lung</td>
</tr>
<tr>
<td>24</td>
<td>NA</td>
</tr>
<tr>
<td>25</td>
<td>Infection in right lower lung and right pleural effusion</td>
</tr>
</tbody>
</table>

*NA, not available.
### Technical Appendix Table 3. Antibody titers in human and mouse serum, and virus titer in mice lungs

<table>
<thead>
<tr>
<th>Serum no.</th>
<th>IgG antibody of human serum</th>
<th>HAI antibody of human serum</th>
<th>MN antibody of human serum</th>
<th>IgG antibody titer in mouse serum</th>
<th>TCID&lt;sub&gt;50&lt;/sub&gt; in mice lungs</th>
</tr>
</thead>
<tbody>
<tr>
<td>S1</td>
<td>200</td>
<td>5</td>
<td>5</td>
<td>20</td>
<td>2.58</td>
</tr>
<tr>
<td>S2</td>
<td>400</td>
<td>10</td>
<td>5</td>
<td>40</td>
<td>2.46</td>
</tr>
<tr>
<td>S3</td>
<td>1600</td>
<td>20</td>
<td>10</td>
<td>20</td>
<td>2.22</td>
</tr>
<tr>
<td>S4</td>
<td>800</td>
<td>20</td>
<td>20</td>
<td>40</td>
<td>2.22</td>
</tr>
<tr>
<td>S5</td>
<td>1600</td>
<td>20</td>
<td>20</td>
<td>20</td>
<td>2.22</td>
</tr>
<tr>
<td>S6</td>
<td>3200</td>
<td>40</td>
<td>40</td>
<td>160</td>
<td>2.28</td>
</tr>
<tr>
<td>S7</td>
<td>6400</td>
<td>80</td>
<td>80</td>
<td>160</td>
<td>2.04</td>
</tr>
<tr>
<td>S8</td>
<td>12800</td>
<td>160</td>
<td>160</td>
<td>320</td>
<td>2.06</td>
</tr>
<tr>
<td>S9</td>
<td>25600</td>
<td>160</td>
<td>640</td>
<td>320</td>
<td>2.04</td>
</tr>
<tr>
<td>S10</td>
<td>12800</td>
<td>320</td>
<td>320</td>
<td>320</td>
<td>2.03</td>
</tr>
<tr>
<td>S11</td>
<td>12800</td>
<td>640</td>
<td>1280</td>
<td>320</td>
<td>2.00</td>
</tr>
<tr>
<td>S12</td>
<td>12800</td>
<td>1280</td>
<td>2560</td>
<td>320</td>
<td>1.83</td>
</tr>
<tr>
<td>PBS</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>5</td>
<td>2.67</td>
</tr>
<tr>
<td>HD</td>
<td>100</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>2.63</td>
</tr>
</tbody>
</table>

*HD, healthy donor; HAI, hemagglutination inhibition; MN, microneutralization; S, serum.*
Technical Appendix Figure 1. Correlation analysis among titers of hemagglutination inhibition (HI), neuraminidase inhibition (NI), microneutralization (MN), IgG, and IgA antibodies against the influenza A(H7N9) virus in survivors.
Technical Appendix Figure 2. Hemagglutination inhibition (HI) antibodies to human seasonal influenza H3 and H1 viruses in survivors and their correlation with HI antibody to the H7N9 virus. A) HI geometric mean titer (GMT) to H1 and H3 subtypes in influenza survivors. B) Correlation between HI antibody to the H7N9 virus and H3 (B) subtype. C) Correlation between HI antibody to the H7N9 virus and H1 subtype.